CS Capannini

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Aim To evaluate the efficacy and safety of MMF in jo-SLE in a multicenter study. test, aCL, antiβ2GPI and LAC at baseline and every 6 months. Disease activity was monitored by the SLEDAI score. Treatment duration was 24 ± 14.8 months (range 2–52). MMF (1.5–2 g/day) was started due to steroid toxicity (n = 9 pts), CyA toxicity (n = 5), disease activity (n =(More)
Purpose Low bone mass has been reported in children with JIA. We wanted to assess areal bone mineral density (BMD) in our cohort of patients and correlate the results with clinical data. Methods The study population included 162 pts (113 F and 49 M, mean age 10.6 ± 3.1 yrs) affected with JIA: 77 oligoarticu-lar, 48 polyarticular RF-, 15 systemic, and 22(More)
  • 1